Early observations and pilot data that first suggested a new direction
For decades, pediatric allergy guidelines recommended strict avoidance of peanut products in high-risk infants until age 3, based on theoretical concerns about sensitization. However, observational data from Israel, where early peanut consumption was common, showed paradoxically lower rates of peanut allergy compared to the UK. The Du Toit 2008 cross-sectional study comparing Jewish children in Israel vs the UK found a 10-fold difference in peanut allergy prevalence (0.17% vs 1.85%), directly challenging the avoidance hypothesis and suggesting that early oral exposure might be protective rather than harmful.
Landmark RCTs and pivotal trials that established the evidence base
The Learning Early About Peanut Allergy (LEAP) trial was a landmark RCT that randomized 640 high-risk infants aged 4-11 months with severe eczema, egg allergy, or both to either consume or avoid peanut until age 5. Results were transformative: peanut allergy developed in only 1.9% of the consumption group vs 13.7% in the avoidance group, an absolute risk reduction of 11.8% and relative reduction of 81%. This single trial fundamentally overturned decades of avoidance-based guidance and represented one of the most dramatic paradigm shifts in modern allergy practice. The LEAP-On follow-up then showed that protection persisted even after 12 months of subsequent avoidance, suggesting durable immune tolerance rather than transient desensitization.
Follow-up studies, subgroup analyses, and real-world validation
Following LEAP, the EAT (Enquiring About Tolerance) trial tested whether early introduction of six allergenic foods (peanut, egg, milk, sesame, fish, wheat) from 3 months of age could prevent allergy in a general population of breastfed infants. While the intention-to-treat analysis was not significant due to adherence challenges, the per-protocol analysis showed a 67% reduction in peanut allergy and significant reductions in egg allergy. Subsequent studies including the PreventADALL trial in Scandinavia and multiple implementation studies confirmed the feasibility and effectiveness of early allergen introduction in real-world settings. The concept expanded beyond peanut to multiple food allergens, establishing a new era of proactive allergy prevention.
Integration into clinical practice guidelines and recommendations
The NIAID Addendum Guidelines published in 2017 represented a complete reversal of prior recommendations, advising early introduction of peanut-containing foods around 4-6 months of age for high-risk infants. This was one of the fastest guideline reversals in allergy history, occurring just 2 years after the LEAP trial. The guidelines stratified infants into three risk categories with specific recommendations for each. The AAP, ASCIA (Australia), and EAACI all subsequently updated their guidelines to align with early introduction, creating a global consensus that early exposure prevents rather than causes food allergy.
NIAID Addendum Guidelines for the Prevention of Peanut Allergy
Introduce peanut-containing foods at 4-6 months for high-risk infants (severe eczema and/or egg allergy); consider SPT or sIgE testing before introduction in highest-risk group
AAP Clinical Report
Early introduction of peanut and other allergenic foods is recommended; no need to delay introduction beyond 4-6 months
EAACI Prevention Guidelines
Early introduction of peanut and well-cooked egg into the infant diet as part of complementary feeding to reduce risk of food allergy
Now
Current standard of care and ongoing research directions
Early peanut introduction is now standard of care globally, with the main implementation challenge being adherence and accessibility of peanut-containing foods for infants. Research has shifted toward understanding optimal dosing, duration, and whether protection extends to other food allergens beyond peanut and egg. Emerging work explores whether combining early introduction with microbiome modulation or emollient therapy could further reduce allergy risk. The field is also investigating biomarkers to identify which infants need testing before introduction versus those who can proceed directly, aiming to simplify guidelines and reduce barriers to implementation.
At what age should peanut-containing foods be introduced to high-risk infants?+
Current guidelines recommend introduction around 4-6 months of age for high-risk infants (those with severe eczema and/or egg allergy). For highest-risk infants, skin prick testing or specific IgE may be performed first, but testing should not delay introduction beyond 6 months.
How strong is the evidence that early peanut introduction prevents allergy?+
The evidence is robust. The LEAP trial showed an 81% relative risk reduction in peanut allergy with early introduction, and the LEAP-On follow-up demonstrated durable protection. This is one of the strongest preventive interventions in allergy medicine, with a number needed to treat (NNT) of approximately 8 for high-risk infants.
Does this approach work for food allergens other than peanut?+
The evidence is strongest for peanut and emerging for egg. The EAT trial suggested benefits for egg allergy as well. For other allergens (milk, sesame, tree nuts), the data is less definitive but guidelines now recommend not delaying introduction of any allergenic food beyond 4-6 months.
What if a child already has eczema—is it safe to introduce peanut?+
Yes, and it is especially important. Infants with eczema are at highest risk for food allergy and stand to benefit most from early introduction. For those with severe eczema, guidelines suggest evaluation by an allergist or testing before introduction, but mild-to-moderate eczema should not delay peanut introduction.
